Navigation Links
Breckenridge Announces Approval for Pioglitazone Hydrochloride tablets
Date:2/13/2013

BOCA RATON, Fla., Feb. 13, 2013 /PRNewswire/ -- Breckenridge Pharmaceutical, Inc. announced today the immediate launch of Pioglitazone Hydrochloride Tablets. The U.S. Food and Drug Administration granted final approval for the Abbreviated New Drug Application (ANDA), which is being manufactured and supplied by Synthon Pharmaceuticals, Inc., and will be available in 15 mg, 30 mg, and 45 mg strengths.  Breckenridge is launching its ANDA prior to patent expiration pursuant to a settlement of Paragraph IV patent litigation with Takeda Pharmaceutical Company Limited and Takeda Pharmaceuticals North America, Inc., who granted Breckenridge and Synthon a license to applicable patents to sell and distribute its ANDA.  Pioglitazone Hydrochloride is AB rated to Actos® a once-daily oral prescription medication that, with diet and exercise, has been shown to be effective for the treatment of type 2 diabetes, and is marketed by Takeda Pharmaceutical. According to industry data, Actos® had approximately $3.7 billion in brand sales for the twelve months ending August 2012, prior to generic competition.  * Actos® is a registered trademark of Takeda Chemical Industries, Ltd.

About Breckenridge:
Breckenridge Pharmaceutical, Inc. is a privately-held pharmaceutical marketing, research and development company founded in 1983 that markets a broad range of generic prescription products in many therapeutic categories.  The Breckenridge label is recognized by Wholesalers, Distributors, Chains, and Managed Care Accounts, as well as Retail Pharmacies nationwide.  The company markets over 70 products in a variety of dosage forms including:  Tablets, Capsules, Soft Gel Capsules, Liquids, Suspensions, and Powders. www.bpirx.com  

About Synthon:
Synthon Pharmaceuticals, Inc., with its U.S. headquarters and laboratories located in Research Triangle Park, North Carolina, markets generic drugs through partnerships with other leading pharmaceutical companies. Synthon currently holds several approved, or tentatively approved, drug applications and has a pipeline containing more than a dozen products that are expected to be filed with the FDA within the next few years. Synthon Pharmaceuticals, Inc. is part of the Synthon group, a global privately held specialty pharma company with offices, laboratories and manufacturing sites in 11 countries worldwide. www.synthon.com


'/>"/>
SOURCE Breckenridge Pharmaceutical, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Regulus Announces Timing for Fourth Quarter and Year-End 2012 Financial Results Webcast and Conference Call
2. CryoLife Announces Quarterly Cash Dividend for the First Quarter 2013
3. Xenon Announces Appointment of EVP, Research & Development
4. BiOptix announces expansion of Innovators Program at Molecular Med TRI-CON 2013
5. OncoGenex Announces Plans for the Initiation of the Borealis-2 Clinical Trial Evaluating OGX-427 in Combination with Second-Line Therapy for Bladder Cancer
6. OrbusNeich Announces Favorable Ruling From the European Patent Office
7. Trovagene Announces Commercial Launch Timelines for HPV Carrier and Oncogene Mutation Tests
8. Comprehensive Care Corporation Announces New Medicare Contract with Humana Health Plan of California, Inc.
9. Unilife Corporation Announces Financial Results For Fiscal Year 2013 Second Quarter
10. Regeneron Announces Receipt of Hart-Scott-Rodino Notice
11. DelMar Pharmaceuticals Announces $1.0 Million Third Closing in Private Placement
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/4/2016)...  Compass Diversified Holdings (NYSE: CODI ) ... leading middle market businesses, announced today its consolidated operating ... First Quarter 2016 Highlights , Generated ... "Cash Flow") of $13.6 million for the first quarter ... million for the first quarter of 2016; , ...
(Date:5/4/2016)... May 4, 2016 Yissum ... announced today that it had signed an exclusive ... , developer of novel protein degradation and immunomodulatory drugs ... commercialization of drug candidates representing first-in-class therapy for hematologic ... not disclosed. The novel technology was developed ...
(Date:5/4/2016)... May 4, 2016 ... the  "Global Acute Myeloid Leukemia Market and ... their offering.       (Logo: ... Leukemia Market and Competitive Landscape Highlights 2016, ... pipeline products, Acute Myeloid Leukemia epidemiology, Acute ...
Breaking Medicine Technology:
(Date:5/5/2016)... Virginia Washington, DC (PRWEB) , ... ... ... Media Contact: Claudia Tellez, Executive Director 703.462.0658, ctellez(at)msnva.org , The Medical Society ... for community physicians and their patients , The Medical Society of Northern ...
(Date:5/5/2016)... ... , ... Linfield College Online and Continuing Education is encouraging registered nurses to ... fee for all qualified applicants from May 1–14. Students need only go to the ... . , With the RN to BSN degree program, all core ...
(Date:5/5/2016)... FL (PRWEB) , ... May 05, 2016 , ... In ... is easy to forget the most important arrangement — planning a safe way of ... celebrations and popular tequila drinks. Unfortunately, these celebrations often lead to drunk drivers on ...
(Date:5/5/2016)... ... May 05, 2016 , ... Is the part in your ... just a few days away, it’s a good opportunity to raise awareness about a ... American Academy of Dermatology, 40% of women experience hair loss or ‘thinning’ by the ...
(Date:5/5/2016)... ... May 05, 2016 , ... BloodHub, the nation’s ... service orders. Blood suppliers and their hospitals use BloodHub for order management, ... active users across 2,100 hospitals who use our platform to processes thousands of ...
Breaking Medicine News(10 mins):